Abstract
Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Current Topics in Medicinal Chemistry
Title: Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Volume: 7 Issue: 1
Author(s): L. D. Estrada and C. Soto
Affiliation:
Keywords: Aggregation inhibitors, β-sheet breakers, amyloid, Alzheimer's disease
Abstract: Alzheimers disease is a devastating degenerative disorder for which there is no cure or effective treatment. Although the etiology of Alzheimers disease is not fully understood, compelling evidence indicates that deposition of aggregates composed by a misfolded form of the amyloid beta peptide (Aβ) is the central event in the disease pathogenesis. Therefore, an attractive therapeutic strategy is to prevent or reverse Aβ misfolding and aggregation. Diverse strategies have been described to identify inhibitors of this process, including screening of libraries of small molecules chemical compounds, rational design of synthetic peptides, assessment of natural Aβ-binding proteins and stimulation of the immune system by vaccination. In this article we describe these different approaches, their principles and their potential strengths and weaknesses. Overall the available data suggest that the development of drugs to interfere with Aβ misfolding and aggregation is a feasible target that hold great promise for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
Estrada D. L. and Soto C., Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318262
DOI https://dx.doi.org/10.2174/156802607779318262 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Aggregation and Self Assembly in Health and Disease
Current Proteomics Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Patent Selections
Recent Patents on Medical Imaging Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Pharmacotherapy of Dilated Cardiomyopathy
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Human Urotensin II and Metabolic Syndrome
Vascular Disease Prevention (Discontinued) The Role of Oxidative Stress in Methamphetamine and MDMA-induced Toxicity
Mini-Reviews in Organic Chemistry What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Luteolin Antagonizes Angiotensin II-Dependent Proliferation and Collagen Synthesis of Cultured rat Cardiac Fibroblasts
Current Pharmaceutical Biotechnology Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Churg-Strauss Syndrome Presenting as Acute Necrotizing Eosinophilic Myocarditis: Concise Review of the Literature
Current Hypertension Reviews Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Therapeutic Strategies of Plant-derived Compounds for Diabetes Via Regulation of Monocyte Chemoattractant Protein-1
Current Medicinal Chemistry Cellular Therapy for Myocardial Repair
Current Cardiology Reviews